The Open Medicine Foundation’s new research concept is based on a collaborative open model, across specialties and countries. “The goal with OMF is to bring all researchers in the ME / CFS community to work together faster. If we can find a way to be open and share information we can find solutions faster.” – Dr. Ron Davis, NOVA Preconference, Florida 2016.
Linda Tannenbaum, president of OMF, hosted and introduced the session on collaboration at the IACFS preconference at NOVA Southeastern University. “My passion is collaboration and that is how the OMF is structured, collaborative and open. This is so important to solve this disease and fast track answers.”
The OMF’s prestigious Scientific Advisory Board (SAB) currently has 12 members, including 3 Noble Laureates and 6 National Academy of Sciences’ Members, some of them part of the Human Genome Project, one of the most groundbreaking research projects of the last 15years. Together these experts cover 18 different medical fields and specialties! Dr. Ron Davis president of our SAB, is meeting weekly with experts of the Chronic Fatigue Syndrome Group at Stanford University. He also works closely together on a daily basis and as needed, with the experts on our SAB and others from Europe, Australia, etc. We will shortly expend our SAB.
At NOVA’s preconference Dr. Ron Davis highlighted why collaboration is so important to solve ME / CFS. “We need to change the way research is done so that we can work together more collaboratively. The publication and review process is very flawed. Personally in a 10 year period I only had 1 review that was helpful. The current review process is compromising studies, distorting literature and slowing down researchers’ ability to publish and share important information.”
Dr. Davis provided the example that he changed the way data was shared during the Human Genome Sequencing Project (where he played a major role in) in such a way that the protocol now is that any sequencing must be posted within 24 hours. This promoted sequencing to move forward faster. Dr. Davis shared two other examples that worked well, cutting through the red tape, The Trauma Study and the Yeast Study. Dr. Davis also stressed that there needs to be a way to share negative results, because negative results are results too and can teach us about the mechanisms. “You can’t publish them, but they do tell you something.”
Dr. Davis finished the session by saying: “OMF is launching a new platform to share the data from our Severely ill Big Data Study so that others can begin to look at it and examine it. Working together we will expedite answers!”